{"id":"brimonidine-0-33","safety":{"commonSideEffects":[{"rate":null,"effect":"Erythema (rebound redness)"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Pallor"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brimonidine selectively binds to alpha-2 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction that reduces blood flow to the skin surface. This mechanism decreases the appearance of facial erythema and flushing. The topical 0.33% formulation is applied directly to affected areas to provide localized anti-erythema effects.","oneSentence":"Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces erythema (redness) in the skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:20.867Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent facial erythema associated with rosacea"}]},"trialDetails":[{"nctId":"NCT07431476","phase":"PHASE4","title":"Brimonidine 0.33% for Rosacea-Related Facial Erythema","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2025-05-01","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":45},{"nctId":"NCT03508869","phase":"NA","title":"Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea","status":"TERMINATED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2016-09-27","conditions":"Erythema and Flushing Associated With Rosacea","enrollment":5},{"nctId":"NCT02249065","phase":"PHASE4","title":"Mirvaso in Use Study","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2014-09","conditions":"Rosacea","enrollment":205},{"nctId":"NCT05401422","phase":"NA","title":"Brimonidine in Rosacea","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-05-25","conditions":"Rosacea","enrollment":45},{"nctId":"NCT02385240","phase":"PHASE3","title":"Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2015-03","conditions":"Rosacea","enrollment":552},{"nctId":"NCT02616250","phase":"PHASE4","title":"MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2015-12","conditions":"Rosacea","enrollment":190},{"nctId":"NCT03497442","phase":"EARLY_PHASE1","title":"Treatment of Asian Flushing Syndrome With Topical Alpha Agonists","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-07-12","conditions":"Flushing, Alcohol-Related Disorders, Aldehyde Dehydrogenase Deficiency","enrollment":20},{"nctId":"NCT02602470","phase":"","title":"Preferences & Treatment Satisfaction Drivers in Rosacea Patients","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01-08","conditions":"Rosacea","enrollment":206},{"nctId":"NCT02289352","phase":"PHASE3","title":"Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2014-07","conditions":"Rosacea","enrollment":462},{"nctId":"NCT02764411","phase":"PHASE3","title":"Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2016-06","conditions":"Capillary Malformations","enrollment":6},{"nctId":"NCT03048058","phase":"PHASE4","title":"Internet Surveys and Their Impact on Adherence for Rosacea","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05-05","conditions":"Rosacea","enrollment":20},{"nctId":"NCT02147691","phase":"PHASE4","title":"Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2014-05","conditions":"Acne Rosacea","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Miravaso","Onreltea"],"phase":"marketed","status":"active","brandName":"Brimonidine 0.33%","genericName":"Brimonidine 0.33%","companyName":"Derm Research, PLLC","companyId":"derm-research-pllc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brimonidine 0.33% is a small molecule used to treat conditions such as rosacea, flushing, and acne rosacea. It is administered as a topical gel, often in comparison to a placebo vehicle gel, in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}